1. Lack of selection of antimalarial drug resistance markers after intermittent preventive treatment of schoolchildren (IPTsc) against malaria in northeastern Tanzania.
- Author
-
Von Wowern F, Makenga G, Wellmann Thomsen S, Wellmann Thomsen L, Filtenborg Hocke E, Baraka V, Opot BH, Minja DTR, Lusingu JPA, Van-Geertruyden JP, Hansson H, and Alifrangis M
- Subjects
- Humans, Tanzania epidemiology, Child, Male, Female, Polymorphism, Single Nucleotide, Quinolines therapeutic use, Child, Preschool, Protozoan Proteins genetics, Multidrug Resistance-Associated Proteins genetics, Genetic Markers, DNA Copy Number Variations, Piperazines, Antimalarials therapeutic use, Antimalarials pharmacology, Malaria, Falciparum epidemiology, Malaria, Falciparum prevention & control, Malaria, Falciparum parasitology, Malaria, Falciparum drug therapy, Plasmodium falciparum drug effects, Plasmodium falciparum genetics, Drug Resistance genetics, Amodiaquine therapeutic use, Artemisinins therapeutic use, Drug Combinations
- Abstract
Objective: Intermittent Preventive Treatment of schoolchildren (IPTsc) is recommended by WHO as a strategy to protect against malaria; to explore whether IPTsc with dihydroartemisinin-piperaquine (DP) or artesunate-amodiaquine (ASAQ) cause a selection of molecular markers in Plasmodium falciparum genes associated with resistance in children in seven schools in Tanga region, Tanzania., Methods: SNPs in P. falciparum genes Pfmdr1, Pfexo, Pfkelch13, and Pfcrt and copy number variations in Pfplasmepsin-2 and Pfmdr1 were assessed in samples collected at 12 months (visit 4, n=74) and 20 months (visit 6, n=364) after initiation of IPTsc and compared with the baseline prevalence (n=379)., Results: The prevalence of Pfmdr1 N86 and Pfexo 415G was >99% and 0%, respectively without any temporal differences observed. The prevalence of Pfmdr1 184F changed significantly from baseline (52.2%) to visit 6 (64.6%) (χ
2 =6.11, P=0.013), but no differences were observed between the treatment arms (χ2 =0.05, P=0.98). Finally, only minor differences in the amplification of Pfmdr1 were observed; from 10.2% at baseline to 16.7% at visit 6 (χ2 =0.98, P=0.32)., Conclusions: The IPTsc strategy does not seem to pose a risk for the selection of markers associated with DP or ASAQ resistance. Continuously and timely surveillance of markers of antimalarial drug resistance is recommended., Competing Interests: Declarations of competing interest No conflicts by any of the authors., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF